injection : deux types de non-observance ?, p.51 ,
The natural history of adult Crohn's disease in population-based cohorts, Am J Gastroenterol, vol.105, pp.289-97, 2009. ,
The potential for disease modification in Crohn's disease, Nature Reviews Gastroenterology & Hepatology, vol.135, issue.2, pp.79-85, 2010. ,
DOI : 10.1016/S0016-5085(04)02215-2
Determinants of compliance: The disease and the mechanics of treatment ,
Measuring adherence with therapy for chronic diseases: Implications for the treatment of heterozygous familial hypercholesterolemia, The American Journal of Cardiology, vol.72, issue.10, pp.68-74, 1993. ,
DOI : 10.1016/0002-9149(93)90014-4
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, The American Journal of Gastroenterology, vol.8, issue.10, pp.2929-2962, 2001. ,
DOI : 10.1046/j.1365-2036.2000.00698.x
A practical perspective on ulcerative colitis: Patients?? needs from aminosalicylate therapies, Inflammatory Bowel Diseases, vol.18, issue.12, pp.1107-1120, 2006. ,
DOI : 10.1046/j.1365-2036.2003.01648.x
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996. ,
DOI : 10.1097/00042737-199612000-00009
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease Compliance to therapy in patients on a maintenance dose of sulfasalazine, Aliment Pharmacol Ther J Clin Gastroenterol, vol.184, pp.191-8333, 1982. ,
Mercaptopurine metabolite results in clinical gastroenterology practice, Alimentary Pharmacology and Therapeutics, vol.118, issue.1, pp.69-73, 2003. ,
DOI : 10.1016/S0016-5085(00)70354-4
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01392.x/pdf
How Adherent to Treatment With Azathioprine Are Patients With Crohn??s Disease in Long-term Remission?, Inflammatory Bowel Diseases, vol.305, issue.6844, pp.446-50, 2007. ,
DOI : 10.1046/j.1365-2036.2003.01392.x
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease, Gut, vol.53, issue.8, pp.1123-1131, 2004. ,
DOI : 10.1136/gut.2003.032896
Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008. ,
DOI : 10.1007/s10620-007-9968-0
Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn???s disease patients, Advances in Therapy, vol.11, issue.suppl.1, pp.936-982, 2009. ,
DOI : 10.1111/j.1524-4733.2007.00213.x
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003. ,
DOI : 10.1016/S0002-9343(02)01383-9
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1 ,
DOI : 10.1053/j.gastro.2006.11.041
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002. ,
DOI : 10.1016/S0140-6736(02)08512-4
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-50, 2007. ,
DOI : 10.1056/NEJMoa062897
Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal ?, Gut, vol.55, p.131, 2006. ,
Adherence rates with infliximab therapy in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.4, issue.7, pp.1099-103, 2006. ,
DOI : 10.1053/cgh.2003.50025
Predictors of Medication Adherence in Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.54, issue.7, pp.1417-1443, 2007. ,
DOI : 10.1097/01.mlr.0000114908.90348.f9
Nonadherence in inflammatory bowel disease: Results of factor analysis, Inflammatory Bowel Diseases, vol.1119, issue.10, pp.1244-1253, 2007. ,
DOI : 10.1016/j.chroma.2006.01.058
Risk factors for non-adherence to medication in inflammatory bowel disease patients ,
Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.24, issue.8, pp.1233-1242, 2009. ,
DOI : 10.1097/00005650-198601000-00007
Adherence to treatment in inflammatory bowel disease, Revista Espa??ola de Enfermedades Digestivas, vol.97, issue.4, pp.249-57, 2005. ,
DOI : 10.4321/S1130-01082005000400005
Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.5, issue.12, pp.2165-2174, 2006. ,
DOI : 10.1007/s10620-006-9444-2
Patients?? attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.64, issue.6, pp.837-881, 2009. ,
DOI : 10.1111/j.1365-2036.2006.02809.x
Psychiatric Predictors of Noncompliance in Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, vol.32, issue.1, pp.66-74, 2001. ,
DOI : 10.1097/00004836-200101000-00015
Clustering patients according to health perceptions, Journal of Psychosomatic Research, vol.56, issue.3, pp.323-355, 2004. ,
DOI : 10.1016/S0022-3999(03)00508-7
Recurrence of Crohn's Disease After Ileocolic Resection Is Not Affected by Anastomotic Type, Diseases of the Colon & Rectum, vol.52, issue.5, pp.919-946, 2009. ,
DOI : 10.1007/DCR.0b013e3181a4fa58
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997. ,
DOI : 10.1056/NEJM199710093371502
An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease, The American Journal of Gastroenterology, vol.52, issue.10, pp.1984-1993, 2004. ,
DOI : 10.1053/gast.2003.50182
Human Anti???Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn???s Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, issue.2, pp.323-356, 2006. ,
DOI : 10.1053/j.gastro.2005.11.030
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab, Annals of Internal Medicine, vol.146, issue.12, pp.829-867, 2007. ,
DOI : 10.7326/0003-4819-146-12-200706190-00159
Certolizumab Pegol for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.228-266, 2007. ,
DOI : 10.1056/NEJMoa067594
How do patients with inflammatory bowel disease want their biological therapy administered?, BMC Gastroenterology, vol.30, issue.3, 2010. ,
DOI : 10.1111/j.1365-2036.2009.04033.x
URL : https://doi.org/10.1186/1471-230x-10-1
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis, Musculoskeletal Care, vol.6, issue.1, pp.1-14, 2008. ,
DOI : 10.7861/clinmedicine.6-1-105
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study), Rheumatology, vol.55, issue.6, pp.289-94, 2009. ,
DOI : 10.1002/art.22355
Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn??s Disease, PharmacoEconomics, vol.13, issue.6, pp.609-630, 2009. ,
DOI : 10.2165/11312710-000000000-00000
Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn???s disease: a cost-effectiveness analysis, Alimentary Pharmacology & Therapeutics, vol.56, issue.11-12 ,
DOI : 10.1177/027298902320556118
Incidence and clinical significance of immunogenicity to infliximab in Crohn??s disease, Inflammatory Bowel Diseases, vol.26, issue.8, pp.1264-75, 2009. ,
DOI : 10.1053/j.gastro.2006.02.038
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial, Gut, vol.56, issue.9, pp.1232-1241, 2007. ,
DOI : 10.1136/gut.2006.106781
Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group, International Journal of Neuroscience, vol.76, issue.1, pp.273-282, 2010. ,
DOI : 10.1212/01.WNL.0000078885.05053.7D
Adherence to combination therapy enhances sustained response in genotype-1???infected patients with chronic hepatitis C, Gastroenterology, vol.123, issue.4 ,
DOI : 10.1053/gast.2002.35950
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study, World Journal of Gastroenterology, vol.14, issue.40, pp.6195-203, 2008. ,
DOI : 10.3748/wjg.14.6195
Hepatitis C patients??? self-reported adherence to treatment with pegylated interferon and ribavirin, Alimentary Pharmacology & Therapeutics, vol.17, issue.Suppl. 3, pp.289-93, 2008. ,
DOI : 10.1097/00126334-200104150-00005
Compliance with subcutaneous erythropoietin in peritoneal dialysis patients, Adv Perit Dial, vol.16, pp.90-92, 2000. ,
Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study, Clinical Therapeutics, vol.29, issue.9, pp.2055-67, 2007. ,
DOI : 10.1016/j.clinthera.2007.09.024
Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis, J Rheumatol, vol.34, pp.2334-2376, 2007. ,
Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?, Arthritis & Rheumatism, vol.354, issue.10, pp.1519-1545, 2008. ,
DOI : 10.1002/art.24114
Trends in RA patients??? adherence to subcutaneous anti-TNF therapies and costs, Current Medical Research and Opinion, vol.25, issue.6, p.8, 2009. ,
DOI : 10.1185/03007990902896386
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis & Rheumatism, vol.64, issue.5, pp.22-32, 2010. ,
DOI : 10.7326/0003-4819-148-2-200801150-00192
Systematic review: adherence issues in the treatment of ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.100, issue.1 ,
DOI : 10.2165/00126839-200506010-00005
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909
Adalimumab, BioDrugs, vol.20, issue.5, pp.125-157, 2007. ,
DOI : 10.2165/00063030-200721020-00007
Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, Inflammatory Bowel Diseases, vol.65, issue.6, pp.763-771, 2008. ,
DOI : 10.1016/j.pec.2006.09.012
The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial, Journal of Hypertension, vol.28, issue.1, pp.194-200, 2010. ,
DOI : 10.1097/HJH.0b013e328331b718
A daily SMS reminder increases adherence to asthma treatment: A three-month follow-up study, Respiratory Medicine, vol.104, issue.2, pp.166-71, 2009. ,
DOI : 10.1016/j.rmed.2009.10.003
Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial, Clinical Therapeutics, vol.28, issue.10, pp.1619-1648, 2006. ,
DOI : 10.1016/j.clinthera.2006.10.006
Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen, Expert Opinion on Biological Therapy, vol.56, issue.2, pp.301-308, 2010. ,
DOI : 10.1093/rheumatology/kel369
HUMIRA® (adalimumab) [en ligne]: www.rxabbott.com/pdf/humira, 2010. ,
Physician-Patient Relationship and Medication Compliance: A Primary Care Investigation, The Annals of Family Medicine, vol.2, issue.5, pp.455-61, 2004. ,
DOI : 10.1370/afm.139
Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies, Alimentary Pharmacology & Therapeutics, vol.20, issue.Suppl. 1, pp.1157-66, 2008. ,
DOI : 10.1155/2005/250504
Improving Adherence Persistence: A Review Assessment of Interventions Description of Steps Toward a National Adherence Initiative, Journal of the American Pharmacists Association, vol.43, issue.6, pp.668-78, 2003. ,
DOI : 10.1331/154434503322642598
Effects of Formal Education for Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial, Canadian Journal of Gastroenterology, vol.19, issue.4, pp.235-279, 2005. ,
DOI : 10.1155/2005/250504
Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence, Annals of Pharmacotherapy, vol.43, issue.3, pp.413-435, 2009. ,
DOI : 10.1177/096228020000900304
Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication, Psychology & Health, vol.149, issue.1, pp.17-32, 2002. ,
DOI : 10.1080/08870449608400270
Development and Testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale, Progress in Cardiovascular Nursing, vol.82, issue.3, pp.90-96, 2000. ,
DOI : 10.1093/ajh/1.3.192S
Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence, Medical Care, vol.24, issue.1, pp.67-74, 1986. ,
DOI : 10.1097/00005650-198601000-00007
Adherence to Medication, New England Journal of Medicine, vol.353, issue.5, pp.487-97, 2005. ,
DOI : 10.1056/NEJMra050100
The Natural History of Adult Crohn's Disease in Population-Based Cohorts, The American Journal of Gastroenterology, vol.132, issue.2, pp.289-97, 2009. ,
DOI : 10.1053/j.gastro.2008.09.053
The potential for disease modification in Crohn's disease, Nature Reviews Gastroenterology & Hepatology, vol.135, issue.2, pp.79-85 ,
DOI : 10.1016/S0016-5085(04)02215-2
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, The American Journal of Gastroenterology, vol.8, issue.10, pp.2929-2962, 2001. ,
DOI : 10.1046/j.1365-2036.2000.00698.x
A practical perspective on ulcerative colitis: Patients?? needs from aminosalicylate therapies, Inflammatory Bowel Diseases, vol.18, issue.12, pp.1107-1120, 2006. ,
DOI : 10.1046/j.1365-2036.2003.01648.x
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996. ,
DOI : 10.1097/00042737-199612000-00009
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease Compliance to therapy in patients on a maintenance dose of sulfasalazine, Aliment Pharmacol Ther J Clin Gastroenterol, vol.184, pp.191-8333, 1982. ,
Mercaptopurine metabolite results in clinical gastroenterology practice, Alimentary Pharmacology and Therapeutics, vol.118, issue.1, pp.69-73, 2003. ,
DOI : 10.1016/S0016-5085(00)70354-4
Adherence to thiopurine treatment in out-patients with Crohn??????s disease, Alimentary Pharmacology & Therapeutics, vol.348, issue.Suppl. 1, pp.217-242, 2007. ,
DOI : 10.1097/01.qai.0000248346.79888.78
How adherent to treatment with azathioprine Page, p.24 ,
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease, Inflammatory Bowel Diseases Gut, vol.1253, pp.1123-1131, 2004. ,
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008. ,
DOI : 10.1016/j.cgh.2008.03.014
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007. ,
DOI : 10.1053/j.gastro.2006.11.041
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002. ,
DOI : 10.1016/S0140-6736(02)08512-4
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-50, 2007. ,
DOI : 10.1056/NEJMoa062897
Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal?, Gut, vol.55, p.131, 2006. ,
How do patients with inflammatory bowel disease want their biological therapy administered?, BMC Gastroenterology, vol.30, issue.3 ,
DOI : 10.1111/j.1365-2036.2009.04033.x
Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008. ,
DOI : 10.1007/s10620-007-9968-0
Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn???s disease patients, Advances in Therapy, vol.11, issue.suppl.1, pp.936-982, 2009. ,
DOI : 10.1111/j.1524-4733.2007.00213.x
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003. ,
DOI : 10.1016/S0002-9343(02)01383-9
Adherence rates with infliximab therapy in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.4, issue.7, p.24 ,
DOI : 10.1053/cgh.2003.50025
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909
Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-882, 1988. ,
DOI : 10.2307/2531595
Adalimumab, BioDrugs, vol.20, issue.5, pp.125-157, 2007. ,
DOI : 10.2165/00063030-200721020-00007
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease, Gastroenterology, vol.137, issue.5 ,
DOI : 10.1053/j.gastro.2009.07.062
Trends in RA patients??? adherence to subcutaneous anti-TNF therapies and costs, Current Medical Research and Opinion, vol.25, issue.6, p.8, 2009. ,
DOI : 10.1185/03007990902896386
Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.5, issue.12, pp.2165-2174, 2006. ,
DOI : 10.1007/s10620-006-9444-2
Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis Risk factors for non-adherence to medication in inflammatory bowel disease patients al. Patient nonadherence to medication in inflammatory bowel disease, Inflamm Bowel Dis Aliment Pharmacol Ther Sewitch MJ, Abrahamowicz M Am J Gastroenterol, vol.142798, issue.31, pp.763-8166, 2003. ,
Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease, p.24 ,